Recent submissions

  • Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial 

    Grenader, T; Waddell, T; Peckitt, C; Oates, J; Starling, N; Cunningham, D; Bridgewater, J (2016-04)
  • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

    Smyth, EC; Verheij, M; Allum, W; Cunningham, D; Cervantes, A; Arnold, D (2016-09)
  • Targeting deficient DNA damage repair in gastric cancer. 

    Young, K; Starling, N; Cunningham, D (2016-09)
    Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has been identified ...
  • Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 

    Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; Atkinson, V; Millward, M; Khou, M; Diem, S; Ramanujam, S; Kong, B; Liniker, E; Guminski, A; Parente, P; Andrews, MC; Parakh, S; Cebon, J; Long, GV; Carlino, MS; Klein, O (2016-05)
    Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced ...
  • Genomic Classification and Prognosis in Acute Myeloid Leukemia. 

    Papaemmanuil, E; Gerstung, M; Bullinger, L; Gaidzik, VI; Paschka, P; Roberts, ND; Potter, NE; Heuser, M; Thol, F; Bolli, N; Gundem, G; Van Loo, P; Martincorena, I; Ganly, P; Mudie, L; McLaren, S; O'Meara, S; Raine, K; Jones, DR; Teague, JW; Butler, AP; Greaves, MF; Ganser, A; Döhner, K; Schlenk, RF; Döhner, H; Campbell, PJ (2016-06)
    Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical ...
  • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. 

    Wentzensen, N; Poole, EM; Trabert, B; White, E; Arslan, AA; Patel, AV; Setiawan, VW; Visvanathan, K; Weiderpass, E; Adami, HO; Black, A; Bernstein, L; Brinton, LA; Buring, J; Butler, LM; Chamosa, S; Clendenen, TV; Dossus, L; Fortner, R; Gapstur, SM; Gaudet, MM; Gram, IT; Hartge, P; Hoffman-Bolton, J; Idahl, A; Jones, M; Kaaks, R; Kirsh, V; Koh, WP; Lacey, JV; Lee, IM; Lundin, E; Merritt, MA; Onland-Moret, NC; Peters, U; Poynter, JN; Rinaldi, S; Robien, K; Rohan, T; Sandler, DP; Schairer, C; Schouten, LJ; Sjöholm, LK; Sieri, S; Swerdlow, A; Tjonneland, A; Travis, R; Trichopoulou, A; van den Brandt, PA; Wilkens, L; Wolk, A; Yang, HP; Zeleniuch-Jacquotte, A; Tworoger, SS (2016-08)
    An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic ...
  • The regulatory isoform rPGRP-LC induces immune resolution via endosomal degradation of receptors 

    Neyen, C; Runchel, C; Schüpfer, F; Meier, P; Lemaitre, B (2016-08-22)
  • Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma. 

    Smyth, EC; Babina, IS; Turner, NC (2017-03)
    FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and ...
  • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. 

    Liu, NQ; Ter Huurne, M; Nguyen, LN; Peng, T; Wang, SY; Studd, JB; Joshi, O; Ongen, H; Bramsen, JB; Yan, J; Andersen, CL; Taipale, J; Dermitzakis, ET; Houlston, RS; Hubner, NC; Stunnenberg, HG (2017-02-14)
    Genome-wide association studies have identified a great number of non-coding risk variants for colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. Identification of ...
  • Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. 

    Gracio, F; Burford, B; Gazinska, P; Mera, A; Mohd Noor, A; Marra, P; Gillett, C; Grigoriadis, A; Pinder, S; Tutt, A; de Rinaldis, E (2017-01-06)
    Despite advancements in the use of transcriptional information to understand and classify breast cancers, the contribution of splicing to the establishment and progression of these tumours has only recently starting to ...
  • BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. 

    Shimelis, H; Mesman, RL; Von Nicolai, C; Ehlen, A; Guidugli, L; Martin, C; Calleja, FM; Meeks, H; Hallberg, E; Hinton, J; Lilyquist, J; Hu, C; Aalfs, CM; Aittomaki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, JJ; Bogdanova, N; Bojesen, SE; Bolla, MK; Borresen-Dale, AL; Brauch, H; Brennan, P; Brenner, H; Broeks, A; Brouwers, B; Bruning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Cheng, CY; Choi, JY; Collée, JM; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Dork, T; Dos Santos Silva, I; Dunning, AM; Fasching, PA; Figueroa, JD; Flyger, H; Garcia-Closas, M; Giles, GG; Glendon, G; Guenel, P; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hogervorst, FB; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Kang, D; Kosma, VM; Kristensen, V; Lai, KN; Lambrechts, D; Le Marchand, L; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Machackova, E; Mannermaa, A; Margolin, S; Marme, F; Matsuo, K; Miao, H; Michailidou, K; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Olswold, C; Oosterwijk, JC; Osorio, A; Peterlongo, P; Peto, J; Pharoah, PD; Pylkäs, K; Radice, P; Rashid, MU; Rhenius, V; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schoemaker, MJ; Seynaeve, CM; Shah, M; Shen, CY; Shrubsole, MJ; Shu, XO; Slager, SL; Southey, MC; Stram, DO; Swerdlow, AJ; Teo, SH; Tomlinson, I; Torres, D; Truong, T; van Asperen, CJ; van der Kolk, LE; Wang, Q; Winqvist, R; Wu, AH; Yu, JC; Zheng, W; Zheng, Y; Leary, J; Walker, LC; Foretova, L; Fostira, F; Claes, K; Varesco, L; Moghadasi, S; Easton, DF; Spurdle, AB; Devilee, P; Vrieling, H; Monteiro, AN; Goldgar, DE; Carreira, A; Vreeswijk, MP; Couch, FJ (2017-03-10)
    Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between ...
  • Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2. 

    Studd, JB; Vijayakrishnan, J; Yang, M; Migliorini, G; Paulsson, K; Houlston, RS (2017-03-03)
    Despite high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL) being the most common subgroup of paediatric ALL, its aetiology remains unknown. Genome-wide association studies have demonstrated association at 10q21.2. ...
  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences. 

    Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; Zou, X; Martincorena, I; Alexandrov, LB; Martin, S; Wedge, DC; Van Loo, P; Ju, YS; Smid, M; Brinkman, AB; Morganella, S; Aure, MR; Lingjærde, OC; Langerød, A; Ringnér, M; Ahn, SM; Boyault, S; Brock, JE; Broeks, A; Butler, A; Desmedt, C; Dirix, L; Dronov, S; Fatima, A; Foekens, JA; Gerstung, M; Hooijer, GK; Jang, SJ; Jones, DR; Kim, HY; King, TA; Krishnamurthy, S; Lee, HJ; Lee, JY; Li, Y; McLaren, S; Menzies, A; Mustonen, V; O'Meara, S; Pauporté, I; Pivot, X; Purdie, CA; Raine, K; Ramakrishnan, K; Rodríguez-González, FG; Romieu, G; Sieuwerts, AM; Simpson, PT; Shepherd, R; Stebbings, L; Stefansson, OA; Teague, J; Tommasi, S; Treilleux, I; Van den Eynden, GG; Vermeulen, P; Vincent-Salomon, A; Yates, L; Caldas, C; van't Veer, L; Tutt, A; Knappskog, S; Tan, BK; Jonkers, J; Borg, Å; Ueno, NT; Sotiriou, C; Viari, A; Futreal, PA; Campbell, PJ; Span, PN; Van Laere, S; Lakhani, SR; Eyfjord, JE; Thompson, AM; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Martens, JW; Børresen-Dale, AL; Richardson, AL; Kong, G; Thomas, G; Stratton, MR (2016-06)
    We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ...
  • Rare Aggressive Behavior of MDM2-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. 

    Ben Salha, I; Zaidi, S; Noujaim, J; Miah, AB; Fisher, C; Jones, RL; Thway, K (2016-09-05)
    Dedifferentiated liposarcoma (DDL) is a histologically pleomorphic sarcoma, traditionally defined as well-differentiated liposarcoma with abrupt transition to high grade, non-lipogenic sarcoma. It can occur as part of ...
  • Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures 

    Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; Farnie, G; Daley, F; Peck, B; Natrajan, R (2016)
  • Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified? 

    Smyth, EC; Tarazona, N; Peckitt, C; Armstrong, E; Mansukhani, S; Cunningham, D; Chau, I (2016-06)
    Strict eligibility criteria are necessary to maintain patient safety and scientific validity in clinical trials. However, this may lead to impaired generalizability of results. As survival in gastrointestinal (GI) cancer ...
  • Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. 

    Winfield, JM; Tunariu, N; Rata, M; Miyazaki, K; Jerome, NP; Germuska, M; Blackledge, MD; Collins, DJ; de Bono, JS; Yap, TA; deSouza, NM; Doran, SJ; Koh, DM; Leach, MO; Messiou, C; Orton, MR (2017-03-14)
    Purpose To assess the repeatability of apparent diffusion coefficient (ADC) estimates in extracranial soft-tissue diffusion-weighted magnetic resonance imaging across a wide range of imaging protocols and patient populations. ...
  • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016) 

    Herrera-Abreu, MT; Palafox, M; Asghar, U; Rivas, MA; Cutts, RJ; Garcia-Murillas, I; Pearson, A; Guzman, M; Rodriguez, O; Grueso, J; Bellet, M; Cortes, J; Elliott, R; Pancholi, S; Lord, CJ; Baselga, J; Dowsett, M; Martin, L-A; Turner, NC; Serra, V (2016-10)
  • DOI: 10.1093/annonc/mdx074 · License: CC BY-NC 4.0 

    Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; McDonald, A; Maka, N; Balsitis, M; Bose, N; Simbolo, M; Mafficin, A; Lampis, A; Hahne, JC; Trevisani, F; Eltahir, Z; Mentrasti, G; Findlay, C; Kalkman, EAJ; Punta, M; Werner, B; Lise, S; Aktipis, A; Maley, C; Greaves, M; Braconi, C; White, J; Fassan, M; Scarpa, A; Sottoriva, A; Valeri, N

View more